Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification

Silvia La Monica¹, Cristina Caffarra¹, Francesca Saccani¹, Elena Galvani¹,², Marica Galetti¹,²,³, Claudia Fumarola¹, Mara Bonelli¹, Andrea Cavazzoni¹, Daniele Cretella¹, Rita Sirangelo¹, Rita Gatti¹, Marcello Tiseo⁵, Andrea Ardizzoni⁵, Elisa Giovannetti²⁵, Pier Giorgio Petronini¹, Roberta R. Alfieri¹**

¹ Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy, ² Department Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands, ³ Italian Workers’ Compensation Authority (INAIL) Research Center at the University of Parma, Italy, ⁴ Department of Biotechnology, Biomedical and Translational Sciences, University of Parma, Parma, Italy, ⁵ Division of Medical Oncology, University Hospital of Parma, Parma, Italy

Abstract

Despite the initial response, all patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). The EGFR-T790M secondary mutation is responsible for half of acquired resistance cases, while MET amplification has been associated with acquired resistance in about 5-15% of NSCLCs. Clinical findings indicate the retained addiction of resistant tumors on EGFR signaling. Therefore, we evaluated the molecular mechanisms supporting the therapeutic potential of gefitinib maintenance in the HCC827 GR5 NSCLC cell line harbouring MET amplification as acquired resistance mechanism. We demonstrated that resistant cells can proliferate and survive regardless of the presence of gefitinib, whereas the absence of the drug significantly enhanced cell migration and invasion. Moreover, the continuous exposure to gefitinib prevented the epithelial-mesenchymal transition (EMT) with increased E-cadherin expression and down-regulation of vimentin and N-cadherin. Importantly, the inhibition of cellular migration was correlated with the suppression of EGFR-dependent Src, STAT5 and p38 signaling as assessed by a specific kinase array, western blot analysis and silencing functional studies. On the contrary, the lack of effect of gefitinib on EGFR phosphorylation in the H1975 cells (EGFR-T790M) correlated with the absence of effects on cell migration and invasion. In conclusion, our findings suggest that certain EGFR-mutated patients may still benefit from a second-line therapy including gefitinib based on the specific mechanism underlying tumor cell resistance.

Introduction

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the world, and traditional chemotherapeutic drugs have only a palliative effect [1]. However, the discovery of epidermal growth factor receptor (EGFR) activating mutations and the response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, deeply changed the management of advanced NSCLC in the last decade [2–4]. Small in-frame deletions in exon 19 and point mutations within exon 21 (L858R) are the most common EGFR activating mutations both leading to sustained activity of the kinase. These mutations increase the susceptibility to EGFR-TKIs activity [5,6] but all the EGFR-mutant lung cancer patients experience disease progression within 10 to 14 months from the beginning of the therapy [7–9]. Various mechanisms of resistance have been identified [10]. The acquisition of the EGFR-T790M secondary mutation is responsible for half of the cases of acquired resistance to EGFR-TKIs [11,12] and MET amplification, allowing cell survival by persistent Akt signaling activation, has been described for 5 to 15% of cases [13–15]. PIK3CA mutations and transformation to SCLC have also been implicated as mechanisms of resistance to EGFR-TKIs [16]. Furthermore, recent studies reported that the epithelial-
mesenchymal transition (EMT), a process in which cells lose their epithelial features and acquire a mesenchymal fibroblastoid phenotype enhancing their motility and invasion capability, might also play a role in the development of resistance to EGFR-TKIs in NSCLC [17,18].

TKI-resistant NSCLC patients are commonly treated with chemotherapeutic drugs. However, several clinical indications suggest that EGFR-mutant lung cancers maintain partial sensitivity to TKIs despite development of acquired resistance and tumors can still be sensitive to EGFR-TKIs treatment beyond progression [19–22] or re-treatment at further progression [23–25]. In addition Chaft and collaborators documented that in a series of patients discontinuing EGFR-TKI prior to enrolling in a clinical trial for acquired resistance, 22% developed accelerated progression leading to hospitalization, occurring after a median of 8 days [26].

Novel strategies under investigation include the continuation beyond progression of EGFR-TKIs combined with chemotherapy, the re-challenge with TKIs after second-line chemotherapy, the use of irreversible TKIs or the combination with novel agents targeting different molecular pathways.

Further preclinical studies to describe molecular mechanisms and potential markers of drug activity are also warranted. Therefore, in this study we explored the retained antitumor activity of gefitinib in resistant HCC827-GR5 and NCI-H1975 NSCLC cells, carrying MET amplification and T790M mutation, respectively.

Our results indicate that HCC827 GR5 cells can proliferate and survive regardless of the presence of gefitinib, whereas its absence enhanced their migrating and invading capabilities and allowed the acquisition of mesenchymal markers (down-regulation of E-cadherin and up-regulation of vimentin and N-cadherin). The maintenance of gefitinib, instead, reduced cell migration or invasion.

These results suggest that patients who are more likely to benefit from continuing gefitinib treatment after tumor progression may be selected based on the mechanisms of acquired resistance to the first-line treatment with EGFR-TKIs.

Materials and Methods

Cell Culture

Human HCC827 GR5 NSCLC cell line was kindly provided by Dr P. Jänne (Dana-Farber Cancer Institute, Boston MA) and it was obtained from gefitinib-sensitive EGFR exon 19 mutant HCC827 cell line by exposing these cells to increasing concentration of gefitinib for 6 months as previously described [13]. Calu-3 and NCI-H1975 (H1975) were from ATCC (Manassas, VA). Cells were cultured as recommended and maintained under standard cell culture conditions at 37°C in a water-saturated atmosphere of 5% CO₂ in air. HCC827 GR5 cells were cultured in the presence of gefitinib 1µM.

Drug treatment

Gefitinib (ZD1839/Iressa®) was provided by AstraZeneca (Milan, Italy). NVP-BEZ235 was provided by Novartis Institutes for BioMedical Research (Basel, Switzerland). Dasatinib was from LC Laboratories (Woburn, MA). U0126 and SU11274 were from Sigma-Aldrich (St. Louis, MO). PD168393 was from Calbiochem (La Jolla, CA). BIBW2992 (afatinib) was from inpatient pharmacy. Drugs were dissolved in DMSO (Sigma) and diluted in fresh medium before use. Final DMSO concentration in medium never exceeded 0.1% (v/v) and equal amounts of the solvent were added to control cells.

Analysis of cell proliferation, cell death and cell cycle

Cell proliferation was evaluated by cell counting in a Bürker hemocytometer by trypan blue exclusion and by crystal violet staining as previously described [27]. Cell viability was evaluated by tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium- bromide] (MTT) assay as previously described [28]. Data are expressed as percent inhibition of cell proliferation versus control cells. Cell death was assessed on stained (Hoechst 33342/PI) cells using fluorescence-microscopy. Distribution of the cells in the cell cycle was determined by PI staining and flow cytometry analysis as described elsewhere [29].

Wound healing assay

A wound-healing assay was performed with the CytoSelect 24-well Wound Healing Assay Kit (Biologs, San Diego, CA.). Wound healing inserts were put into 24-well cell culture plates and cell suspension (1.5x10⁵ cells in 250 µl) was added to either side of the insert and incubated overnight to form a monolayer. The inserts were then removed to allow the cells to migrate. After 24 hours cells were fixed with 100% methanol, stained with hematoxylin. Images of wound healing were captured by microscope equipped with digital camera at a magnification of ×40 at zero time point and after 24h. Cell migration was quantified by measuring the migration distances. Percent closure was calculated as wound area 24h/wound area zero time point x 100.

Cell migration and invasion

The migration and invasion assays were carried out using Transwell chamber with 6.5-mm diameter polycarbonate filters (8µm pore size, BD Biosciences, Erembodegem, Belgium) uncoated or coated with Matrigel®. Cells were trypsinized and 2x10⁵ cells suspended in serum free RPMI-1640 medium and loaded in the upper wells. FBS (10%) was used as a chemoattractant in the lower chambers. After incubation for 16 hours all of the non-migrated (or non-invaded) cells were removed with a cotton swab, and cells that have migrated (or invaded) through the membranes were fixed with 100% methanol, stained with hematoxylin and counted under a Phase contrast microscope.

Gelatine zymography

The gelatin zymography was performed to determine the activity of matrix metalloproteinases (MMP). Equal number of
cells were seeded and incubated with serum-free RPMI-1640 for 24h in the presence or in the absence of gefitinib 1 µM. Medium was collected and centrifuged at 1800 rpm for 5 min to remove cell debris. Equal amounts of media were mixed with SDS-PAGE sample buffer 4X in the absence of reducing agent and electrophoresed in 10% polyacrylamide gel containing 1mg/ml gelatin. After running, the gel was incubated in the Renaturing Buffer (50mM Tris-HCl pH 7, 6.5mM CaCl$_2$, 1µM ZnCl$_2$, 2.5% Triton X-100) two times for 15 min at room temperature. The gel was washed with Washing Buffer (50mM Tris-HCl pH 7, 6.5mM CaCl$_2$, 1µM ZnCl$_2$) and then it was incubated in Developing Buffer (50 mM Tris-HCl pH 7, 6.5 mM CaCl$_2$, 1µM ZnCl$_2$, 1% Triton X-100, 0.02% NaN$_3$) overnight at 37°C. The gel was stained with 0.25%. Coomassie Brilliant Blue R-250 solution containing 45% methanol and 10% glacial acetic acid for 4 hours and then washed with a solution containing 10% glacial acetic acid, 45% methanol for 3 hours. Areas of protease activity appeared as clear bands. The activity of MMPs was determined by densitometric scanning of the bands and analysis by Quantity One 1-D Analysis Software (BIO-RAD, Hercules, CA).

**Soft agar assay**

Cells were suspended in RPMI1640 containing 0.3% low melting agarose, and plated onto solidified 0.5% agar containing RPMI1640 in six-well culture plates at a density of 10000 cells per well. Cells were incubated at 37°C in 5% CO$_2$ incubator and once a week fresh culture medium was added in each well. After 4 weeks colonies were stained with 0.005% crystal violet and quantified under a phase contrast microscope.

**Western blot analysis**

Procedures for protein extraction, solubilization, and protein analysis by 1-D PAGE are described elsewhere [28]. Antibodies against p-EGFR$^{Tyr1068}$, EGFR, MET, p-Src$^{Tyr416}$, p-Src$^{Tyr422}$, Src, p-Akt$^{Thr389}$, Akt, p70S6K, p70S6K, p-Erk1/2, ERK1/2, p-p38 MAPK, p38 MAPK; p-STAT5$^{Y694}$, STAT5, E-cadherin, N-cadherin, vimentin, SNAIL, Slug were from Cell Signaling Technology (Beverly, MA); antibody against GAPDH was from Ambion (Austin, TX). HRP-conjugated secondary antibodies were from Pierce (Rockford, IL) and chemiluminescence system (Immobililon Western Chemiluminescent HRP Substrate) was from Millipore (Millipore, Temecula, CA). Reagents for electrophoresis and blotting analysis were from BIO-RAD.

**Determination of pattern of protein phosphorylation**

Relative levels of phosphorylation of 46 kinase phosphorylation sites (38 selected proteins) were obtained by using Proteome Profiler Human Phospho-kinase Array (Kit ARY003B from R&D System, Minneapolis, MN) according to the manufacturer’s guidelines. A total of 300µg of proteins was used for each array. The resulting spots were quantified using Quantity One 1-D Analysis Software (BIO-RAD).
Statistical analysis

Statistical analyses were carried out using GraphPad Prism version 5.00 software (GraphPad Software, San Diego, CA). Results are expressed as mean values ± standard deviations (SD) for the indicated number of independent measurements. Differences between the mean values recorded for different experimental conditions were evaluated by Student's t-test, and P values are indicated where appropriate in the figures and in their legends. Significance of difference is indicated as ***P<0.001, **P<0.01 and *P<0.05.

Results

Gefitinib inhibits cell migration, invasion and anchorage independent growth in HCC827 GR5 cells

As previously reported [13] and independently confirmed in our laboratory (data not shown), the gefitinib-resistant clone HCC827 GR5 showed a 1000-fold higher IC_{50} than the parental cell line HCC827 (10 μM versus 10nM, respectively) and is characterized by amplification of the MET oncogene, leading to ERBB3-mediated activation of PI3K/AKT signaling. Src protein activation was also markedly increased supporting a key role of Src signaling in gefitinib-resistance, as reported previously [30].

After a 10 days gefitinib removal the HCC827 GR5 cells did not modify either the proliferation index (Figure 1A) or the cell cycle distribution (Figure 1B) as compared to HCC827 GR5 cells grown in the presence of 1µM gefitinib. Comparable results were obtained after 30 days of gefitinib removal (not shown). Moreover, the absence of gefitinib did not alter HCC827 GR5 resistance to gefitinib for up to 90 days of deprivation. Indeed, as shown in Figure 1C, cells deprived of gefitinib for different periods of time and acutely treated with the drug for 72h still maintained the resistant phenotype (IC50>7μM). The 20-30% of cell growth inhibition observed at 1µM might be ascribed to the presence of a small sub-population of previously quiescent gefitinib-sensitive cells that during the period of gefitinib deprivation might expand and subsequently arrested when re-exposed to the drug. The restoration of drug sensitivity after EGFR TKI withdrawal has been previously reported by Chmielecki et al. in T790M resistant PC9 cells after multiple passages without the inhibitor [31].

HCC827 GR5 cells cultured in the absence of gefitinib for 10 days showed a significant increase in both cell migration and invasion as detected by wound healing and Boyden chambers assay. HCC827 GR5 cells spread into the wound area more efficiently than cells continuously exposed to gefitinib, with wound closure percentages of 48±4.2 and 37±3.2 respectively (P<0.01, Figure 2A). Moreover, as shown in Figure 2B, the HCC827 GR5 gefitinib-deprived, compared to HCC827 GR5 cells cultured with gefitinib, exhibited 2.7-fold increase in the number of migrating cells through the uncoated PET membrane in Boyden chambers. Furthermore, we observed a 3-fold increase in invading cells through the Matrigel-coated PET membrane for the HCC827 GR5 gefitinib-deprived cells (Figure 2C). Considering the role of matrix metalloproteinases (MMPs) in degrading extracellular matrix components, the effect of gefitinib removal on the proteolytic activity of MMP-2

Figure 1. Effect of gefitinib withdrawal on cell proliferation. (A) HCC827 GR5 grown in the presence of 1 μM gefitinib and HCC827 GR5-G (maintained in the absence of gefitinib for 10 days) cells were seeded in a 96-multiwell plate. After 24, 48 and 72h cell proliferation was assessed using crystal violet staining; cell proliferation index was calculated as the ratio between the OD at each point time and the OD at zero time point. Mean values of three independent experiments (±SD) are shown. (B) 24h from seeding, HCC827 GR5 and HCC827 GR5-G were stained with propidium iodide and analyzed by flow cytometry. Cytofluorimetric profiles and percentages of cells residing in each cycle phase are from a representative experiment of three independent experiments. (C) HCC827 GR5 cells gefitinib-deprived for the indicated period of time were exposed for 72h to different concentrations of gefitinib (1 to 40 μM) and then cell growth was assessed using MTT assay. Data are expressed as percent inhibition of cell proliferation versus control cells and are means (±SD) of three independent experiments.

doi: 10.1371/journal.pone.0078656.g001
and MMP-9 was evaluated by using a gelatin zymography assay showing an approximately 2 fold increase of MMP-2 and MMP-9 activity in cells deprived of gefitinib for 10 days. These results indicate that the maintenance of gefitinib inhibited secretion and activation of gelatinolytic MMP-2 and MMP-9 (Figure 2D).

The effect of gefitinib withdrawal on the anchorage-independent growth was also examined by using the soft agar
Gefitinib inhibits signal transduction pathway involved in cellular motility

Increased motility was observed in HCC827 GR5 cells after 3 days of gefitinib withdrawal (Figure 3A). A plateau of cellular migration was reached after 7 days and this phenomenon correlates with the increase in EGFR, and Src\(^{Tyr416}\) phosphorylation (Figure 3B). Moreover, we observed a marked reduction in Src\(^{Tyr416}\) phosphorylation, which negatively regulates Src kinase activity after 7 days since gefitinib withdrawal. By contrast, no differences were detected for MET, Akt and ERK 1/2 phosphorylation status. To better investigate the signaling pathways activated after 7 days of gefitinib removal, 43 specific Ser/Thr or Tyr phosphorylation sites of 35 different proteins were analyzed by a human phospho-kinase array kit. Eight proteins, including p38α, EGFR, Src\(^{Tyr416}\), Lyn, STAT2, STAT6, STAT5a/b and e-Jun, exhibited a significant increase (p<0.05) in their phosphorylation status following gefitinib removal (Figure 3C). The increased phosphorylation of p38, STAT5 and Src was validated by Western blotting in cells deprived of gefitinib for 7 days (Figure 3D).

EGFR modulation correlates with gefitinib-related regulation of cell motility

To assess the role of EGFR re-activation in the acquisition of migratory capability, HCC827 GR5 cells maintained for 10 days in the absence of gefitinib were transfected with EGFR-specific or scramble siRNAs. EGFR expression was verified by Western blotting 72 hours post-transfection (Figure 4A). One µM gefitinib was added, where indicated, 24 hours before blotting. As expected, siRNA- EGFR completely inhibited EGFR expression compared to the negative siRNA-scramble control. As shown in Figure 4B, the inhibitory effect on cell migration obtained by silencing EGFR in HCC827 GR5 cells was similar to the one observed in the presence of gefitinib. Moreover, the addition of gefitinib to siRNA-EGFR transfected cells did not further decrease the amount of migrating cells. These results demonstrated the dependency of HCC827 GR5 cells motility on EGFR activity and suggested that the observed effect of gefitinib on cell migration is associated with the inhibition of its target.

To confirm the involvement of EGFR in controlling cell migration, the effect of gefitinib was evaluated in H1975 cells harbouring EGFR-T790M. This mutation restores EGFR activity by increasing the affinity of the receptor for ATP, thereby competitively displacing reversible EGFR-TKIs, such as gefitinib [12]. As shown in the representative blots in Figure 5A, gefitinib did not affect migration or invasion of H1975 cells presumably due to its lack of effect on EGFR and Src phosphorylation (Figure 5B, C, D). In contrast, the second-generation inhibitors PD168393 and BIBW2992 (afatinib), which are able to covalently interact with Cys797 in the catalytic domain of EGFR, inhibited both EGFR and Src phosphorylation leading to the reduction of cell migration and invasion. Similar results were obtained in H1975 cells with novel irreversible inhibitors recently synthesized by our group [32].

EGFR and MET independently control cellular migration via Src signaling

To unravel the contribution of different signaling pathways in the increased migratory capability, dasatinib (Src inhibitor), SU11274 (MET inhibitor), U0126 (ERK1/2 inhibitor), and NVP-BEZ235 (PI3K/mTOR inhibitor) were tested in HCC827 GR5 cells gefitinib-deprived for 7 days by Boyden chambers assay.

Treatment with U0126 or NVP-BEZ235 did not affect migration of HCC827 GR5 cells deprived of gefitinib for 7 days. By contrast SU11274 inhibited cell migration with results similar to those achieved with gefitinib. Moreover, dasatinib and the combination of gefitinib with SU11274 almost completely suppressed migration (Figure 6A). The single drug concentrations used were able to completely suppress the phosphorylation of the respective targets (not shown), and the drugs that impaired cell migration, at the dose used, did not affect cell proliferation and cell viability at least until 24 hours (Figure 6B). These findings suggest that cell migration was controlled by both EGFR and MET through Src activation.

In order to further confirm these results and the data shown in Figure 3C and 3D documenting up-regulation of Src, STAT5 and p38 after gefitinib deprivation, HCC827 GR5 cells maintained for 7 days in the absence of gefitinib were transfected with siRNAs targeting of Src, STAT5a/b or p38α. We found that knock-down of Src, STAT5a/b or p38α resulted in an almost complete suppression of expression of the corresponding proteins (Figure 6C) and significantly inhibited cell migration induced by gefitinib deprivation compared to the negative siRNA-scramble control (Figure 6D).

Gefitinib inhibits epithelial-mesenchymal transition

To assess the involvement of EMT in the enhanced cell migration and invasion after gefitinib removal, mesenchymal associated features were evaluated. On the molecular level, EMT is defined by down-regulation of E-cadherin and increased expression of N-cadherin and vimentin. E-cadherin expression is regulated by the Wnt/β-catenin-mediated transcription of zinc-finger proteins such as SLUG and SNAIL [33]. As reported in Figure 7A, gefitinib removal induced a decrease in E-cadherin expression while the expression level of N-cadherin, vimentin and negative regulators β-catenin, SLUG and SNAIL were increased compared to cells continuously maintained with gefitinib. Moreover, an increase in the expression of the tight junction protein Claudin-1, recently reported to have a pivotal role in the induction of the EMT program, was also observed [34]. Unexpectedly, these markers of EMT appeared after 21 days of gefitinib removal whereas enhanced motility was observed already after 3 days (see Figure 3A).

Immunofluorescence confocal microscopy confirmed the decrease of E-cadherin expression on the cell membrane and the increased levels of vimentin after 30 days of gefitinib removal (Figure 7B).
A significant increase of vimentin was also detected at gene expression level by qRT-PCR after 15 days of gefitinib removal as compared to gefitinib maintenance (Figure 7C).

Since the transforming growth factor-β1 (TGF-β1) has been recently reported to induce EMT phenotype in human lung cancer cells [35,36] we analyzed whether gefitinib could inhibit TGF-β1-induced EMT. HCC827 GR5 and Calu-3 cells (a NSCLC cell line with epithelial features as previously reported [37]) were treated with 2 ng/ml TGF-β1 for 72 hours with or without 1µM gefitinib. As shown in Figure 7D, TGF-β1 treatment induced an increase of vimentin expression which was partially reverted by addition of gefitinib in the culture medium.

These results confirm the involvement of TGF-β1 in the transforming process to mesenchymal phenotype and indicate the potential role of gefitinib in counteracting EMT after tumor progression.

Figure 3. Effect of gefitinib withdrawal on signal transduction pathways. HCC827 GR5 cells were deprived of gefitinib for 1, 2, 3, 4, 7, 15 or 30 days. (A) Migration assay was performed at each time point. Columns, means of 10 field counted; bars, SD. **P<0.01, ***P<0.001. (B) Expression of the indicated proteins was analyzed by Western blotting at each time point. Results are representative of three independent experiments. (C) HCC827 GR5 grown in the presence of 1 µM gefitinib and HCC827 GR5-G (maintained in the absence of gefitinib for 7 days) lysates were incubated with human phospho-kinase array membranes and bound phospho-proteins were detected according to kit instructions. Each membrane contains specific kinase and positive control antibodies (P) spotted in duplicate. Columns, means of relative levels of protein phosphorylation (ratio of phosphorylation of HCC827 GR5-G/ HCC827 GR5 cells) of duplicate spots 1-9 from a single experiment; bars, SD. Eight proteins (EGFR, p38α, Src, Lyn, STAT2, STAT6, STAT5a/b and c-Jun) exhibited a significant increase (P<0.05) in their phosphorylation status following gefitinib removal (D). Lysates were analyzed by Western blotting using the indicated antibodies.

doi: 10.1371/journal.pone.0078656.g003
Discussion

One of the major findings of our study is that, independently from the effect on cell proliferation and growth, maintenance of gefitinib potentially limit the acquisition of a migratory and invasive phenotype in NSCLC cells characterized by MET amplification-driven resistance. We also demonstrated that gefitinib withdrawal leads to EGFR signaling reactivation, which is involved in the acquisition of cell aggressiveness behaviour. In particular, despite amplification of MET, whose migration/invasion-promoting activity is well established, our results suggest that persistent inhibition of EGFR is sufficient to maintain a low invasive phenotype in HCC827-GR5 gefitinib-resistant cells. These data support the role of EGFR in cell motility and invasiveness and suggest the importance of EGFR-TKIs maintenance treatment after tumor progression.

Of note, the continuous exposure of H1975 cells, carrying the T790M mutation, to gefitinib did not modify their migratory phenotype, possibly because of the low affinity of the mutated receptor for this drug. Indeed, irreversible EGFR-TKIs such as PD168393 or BIBW2992 significantly reduced H1975 cell migration and invasion, confirming the importance of EGFR in controlling these processes.

A number of studies investigated the cross talk between MET and EGFR demonstrating its contribution to cancer growth, migration and invasion [38–40]. Activation of these two receptors initiate similar signal transduction pathways including Src signaling. In HCC827 GR5 cells, only the combination of gefitinib with the MET-TKI PHA-665752 was shown to inhibit proliferation and to induce cell death. These cells were resistant to both gefitinib and PHA-665752 alone, indicating that either EGFR or MET signaling were essential to sustain cell proliferation and viability [13]. Conversely, the Src inhibitor dasatinib alone was able to overcome gefitinib resistance in this cell line [30].

Notably our results indicate that migration can be inhibited with the same efficacy by treating HCC827 GR5 cells with gefitinib or the MET inhibitor SU11274 as single treatment, suggesting their parallel and independent control in cell migration process. Combined inhibition of EGFR and MET resulted in a further inhibition of cell migration and a similar result was obtained with the Src inhibitor dasatinib.

Src and other members of its family of kinases such as Lyn or Fyn, exert a key role in cell migration and invasion through multiple downstream mediators including STAT, CAS, PI3K, FAK, paxillin, and others [41]. Some of these pathways emerged also in our studies, using a phospho-kinase array, that showed the active involvement of eight phosphorylated kinases (EGFR, p38α, Src, Lyn, STAT2, STAT6, STAT5a/b and c-Jun), in early processes associated with cell motility and invasiveness which can be modulated by gefitinib despite tumor progression. The functional role of Src, STAT5a/b and p38α proteins in modulating the migratory properties of HCC827 GR5 cells in response to gefitinib deprivation was further confirmed by siRNA-mediated silencing experiments.

STAT5a/b activation has been previously associated with increased migration and invasion, suppression of cell surface expression of E-cadherin and metastatic dissemination of
In this study we demonstrated that in gefitinib-deprived HCC827 GR5 cells STAT5 was further phosphorylated at the phosphorylation site Tyr^694 residue which is known to be associated with EGFR-dependent Src activation [43], whereas the JAK phosphorylation site Tyr^699 was not modified. Significant modulation of other STAT family members, such as STAT2 and STAT6 was also observed in this study. STAT6 over-expression and activity have been previously reported to correlate with promotion of cell migration in prostate cancer cells [44] and invasiveness growth in glioblastoma [45]. Further studies are warranted to clarify the role of these proteins in cancer invasiveness.

The involvement of p38 in the modulation of cell motility and invasiveness through the regulation of MMPs has also been described [46]. In particular, members of the S100 family of calcium-binding proteins promoted cell migration and invasion through p38 MAPK-dependent NF-κB activation which increased MMP-2 and MMP-12 expression in gastric cells [47]. Moreover, baicalin suppressed cell migration and invasiveness in breast cancer MDA-MB-231 cells by down-regulating p38 MAPK pathway and consequently MMP-2 and MMP-9 expression [48]. In agreement with these and other previous studies, our results showed that gefitinib-treated NSCLC cells with MET amplification display a significant reduction in both MMP-2 and MMP-9 proteolytic activity associated with reduced phosphorylation of p38 MAPK. This modulation was detected by both phospho-kinase array and Western blot, and might be attributed to the direct effect of gefitinib.

There is a growing evidence that EMT contributes to invasive and metastatic tumor growth [49]. EMT is a complex process mainly characterized by down-regulation of markers commonly expressed in epithelial cells (e.g. E-cadherin), and increased expression of mesenchymal markers such as N-cadherin and vimentin. Src activation is a potent trigger for EMT induction [41], causing dissociation of the E-cadherin/β-catenin complex and degradation of E-cadherin by promoting its phosphorylation, ubiquitination, endocytosis and lysosomal degradation [50].

Importantly, we demonstrated that gefitinib maintenance after acquisition of resistance is essential to inhibit phenotypic changes associated with EMT. Moreover, gefitinib can prevent the EMT mediated by TGF-β1 and this might also control resistance to apoptosis and the emergence of stem cell like properties as described in previous studies on EMT [49].

In conclusion, we demonstrated that despite tumor progression after treatment with EGFR-TKIs, NSCLCs with MET amplification are still dependent on EGFR signaling. In these tumors EGFR plays an important role in cell motility and invasiveness and prompts the EMT process possibly via Src signaling. For all these reasons, the maintenance of gefitinib after tumor progression emerges as an important new...
Figure 6. Effect of signal transduction pathways inhibition on cell migration of HCC827 GR5 cells deprived of gefitinib. (A) HCC827 GR5-G (maintained in the absence of gefitinib for 7 days) cells were exposed to dasatinib 0.01 μM, SU11274 1 μM, U0126 10 μM, NVP-BEZ235 0.1 μM, gefitinib 1 μM or SU11274 1 μM + gefitinib 1 μM during migration time. Columns, means of 10 fields counted; bars, SD. Result is representative of three independent experiments. (B) HCC827 GR5-G cells were incubated with dasatinib 0.01 μM, SU11274 1 μM, gefitinib 1 μM or SU11274 1 μM + gefitinib 1 μM. After 24 h cells were counted and cell death was evaluated by fluorescence microscopy on Hoechst/PI stained cells. Columns, means of three independent experiments *, significance vs HCC827 GR5-G. **P<0.01, ***P<0.001, ****P<0.001. HCC827 GR5-G were transfected with Src, STAT5a/b, p38α siRNA or control siRNA (scramble) for 48 h. Then medium was replaced with fresh medium for 16 h and the expression of the indicated proteins was analyzed by Western blotting (C) or cells were seeded on culture inserts for migration assay (D). Columns, means of 10 fields counted; bars, SD. Results are representative of three independent experiments. ***P<0.001.

doi: 10.1371/journal.pone.0078656.g006

therapeutic strategy to inhibit EGFR-mediated aggressive behaviour in NSCLC with MET amplification.
Figure 7. Effect of Gefitinib on EMT. (A) HCC827 GR5 cells were deprived of gefitinib for 1, 7, 14, 21, or 30 days. Expression of the indicated proteins was analyzed by Western blotting at each time point. Results are representative of three independent experiments. (B) Confocal immunofluorescence analysis of HCC827 GR5 and HCC827 GR5-G (maintained in the absence of gefitinib for 30 days) with antibody against E-cadherin and vimentin (green fluorescence). The nuclei were stained with Draq5 (blue fluorescence). Scale Bar: 10 μm. (C) Comparison of vimentin mRNA by quantitative RT-PCR in HCC827 GR5 gefitinib-maintained cells versus gefitinib-deprived cells. The fold change was calculated using the $2^{-\Delta\Delta CT}$ method relative to gefitinib-maintained cells used as control. (D) HCC827 GR5 cells were incubated with 2ng/ml TGF β1 in the absence or in the presence of gefitinib 1μM. After 3 days, protein expression was assessed by Western blotting using the indicated antibodies. Results are representative of three independent experiments. *P<0.05.

doi: 10.1371/journal.pone.0078656.g007
References

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. doi:10.1056/NEJMoa040938. PubMed: 15119073.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. doi:10.1126/science.1099314. PubMed: 15118216.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K et al. (2004) EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13303-13308. doi:10.1073.pnas.040520101. PubMed: 15329413.
5. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227. doi:10.1016/j.ccr.2006.12.017. PubMed: 17349580.
6. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171. doi:10.1158/0008-5472.CAN-06-0453. PubMed: 16912195.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. doi:10.1056/NEJMoa0810699. PubMed: 19892680.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128. doi:10.1016/S1470-2045(09)70364-X. PubMed: 20228099.
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B et al. (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246. doi:10.1016/S1470-2045(12)72208-0. PubMed: 22285168.
10. Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S et al. (2013) Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des 19: 818-832. doi:10.2174/13816128138457222. PubMed: 22273983.
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792. doi:10.1056/NEJMoa044238. PubMed: 15728811.
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med 2: e73. doi:10.1371/journal.pmed.0020073. PubMed: 15737014.
13. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland G et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043. doi:10.1126/science.1141478. PubMed: 17463250.
14. Bean J, Brennan C, Shih JY, Riely G, Viale A et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937. doi:10.1073/pnas.0710370104. PubMed: 18093943.
15. Yu H, Arclia ME, Rekhtman N, Sima CS, Zakowski MF et al. (2013) Analysis of Mechanisms of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR-mutant Lung Cancers. Clin Cancer Res.
16. Sequist LV, Wattman BA, Dias-Santagata D, Digumarthy S, Turke AB et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26. PubMed: 21430269.
17. Thomson S, Petli F, Sukja-Kock I, Epstein D, Haley JD (2008) Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 25: 843-854. doi:10.1007/s10585-008-9200-4. PubMed: 18696232.
18. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8868-8869. doi:10.1158/1078-0432.CCR-05-1492. PubMed: 16361555.
19. Asami K, Okuma T, Hirashima T, Kawaiha M, Atagi S et al. (2013) Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer 79: 276-282. doi:10.1016/j.lungcan.2012.11.022. PubMed: 23261321.
20. Faehling M, Eckert R, Kamp T, Kuom S, Griese U et al. (2013) EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. Lung Cancer 80: 306-312. doi:10.1016/j.lungcan.2013.02.010. PubMed: 23489557.
21. Nishio K, Kawaguchi T, Tamiya A, Minnori T, Takeuchi N et al. (2012) Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 7: 1722-1727. doi:10.1097/JTO.0b013e31826913f7. PubMed: 23059777.
22. Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH et al. (2013) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79: 283-286. doi:10.1016/j.lungcan.2012.11.007. PubMed: 23324265.
23. Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H et al. (2011) Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 11: 1. doi:10.1186/1471-2407-11-1. PubMed: 21194487.
24. Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT et al. (2007) Prospective assessment of discontinuation and reintituation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13: 5150-5155. doi:10.1158/1078-0432.CCR-07-0560. PubMed: 17785570.
25. Hata A, Katakami N, Kaji R, Fujita S, Imai Y (2013) Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 8: e27-e29. doi:10.1097/JTO.0b013e318282e047. PubMed: 23407566.
26. Chafe JE, Oxnard GR, Sima CS, Kris MG, Miller VA et al. (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17: 6298-6303. doi:10.1158/1078-0432.CCR-11-1468. PubMed: 21856766.
27. La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Ardizzone A et al. (2009) Everolimus restores gefitinib sensitivity in resistant non-small
Continuing Gefitinib in Drug-Resistant NSCLC Cells

cell lung cancer cell lines. Biochem Pharmacol 78: 460-468. doi: 10.1016/j.bcp.2009.04.033. PubMed: 19427302.

28. Cavazzone A, Alfieri RR, Carmi C, Zuliani V, Galetti M et al. (2008) Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther 7: 361-370. doi:10.1158/1535-7163.MCT-07-1422. PubMed: 18505878.

29. Fumurato C, La Monica S, Alfieri RR, Borra E, Guidotti GG (2005) Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death Differ 12: 1344-1357. doi:10.1038/sj.cdd.4401660. PubMed: 15905878.

30. Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y et al. (2010) Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small lung cancer cells with acquired MET amplification. Cancer Sci 101: 167-172. doi:10.1111/j.1349-7006.2009.01368.x. PubMed: 19804422.

31. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K et al. (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3: 90ra59. PubMed: 21734175.

32. Galvani E, Giovannetti E, Saccani F, Cavazzone A, Leon LG et al. (2013) Molecular mechanisms underlying the antitumor activity of 3-aminoopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Neoplasia 15: 61-72. PubMed: 23359111.

33. Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 24: 7443-7454. doi:10.1038/sj.onc.1209091. PubMed: 16282891.

34. Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS et al. (2012) Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene (. (2013)) PubMed: 23610379.

35. Maitah MY, Ali S, Ahmad A, Gadgeel S, Sarkar FH (2011) Up-regulation of sonic hedgehog contributes to TGF-beta1-induced epithelial to mesenchymal transition in NSCLC cells. PLOS ONE 6: e16068. doi:10.1371/journal.pone.0016068. PubMed: 21249152.

36. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H et al. (2011) Epithelial to mesenchymal transition in an epithelial growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-1161. doi:10.1097/JTO.0b013e31821ee6e2. PubMed: 21597390.

37. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K et al. (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950. doi:10.1158/0008-5472.CAN-05-1988. PubMed: 16424029.

38. Jo M, Stoiz DB, Esplen JE, Dorko K, Michalopoulos GK et al. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811. doi:10.1074/jbc.275.12.8806. PubMed: 10722725.

39. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU et al. (2002) Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8: 2273-2285. PubMed: 12114431.

40. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105: 692-697. doi:10.1073/pnas.0707270105. PubMed: 18180459.

41. Guarino M (2010) Src signaling in cancer invasion. J Cell Physiol 223: 14-26. PubMed: 20049846.

42. Gu L, Vogiatzi P, Puhr M, Dadvadorj A, Lutz J et al. (2010) Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 17: 481-493. doi:10.1677/ERC-09-0328. PubMed: 20233708.

43. Quesnelle KM, Boehm AL, Grandis JR (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102: 311-319. doi:10.1002/jcb.21475. PubMed: 17661350.

44. Das S, Roth CP, Wasson LM, Vishwanatha JK (2007) Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67: 1550-1564. doi:10.1002/pros.20640. PubMed: 17705178.

45. Merk BC, Owens JL, Lopes MB, Silva CM, Hussain IM (2011) STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer 11: 184. doi:10.1186/1471-2407-11-184. PubMed: 21595984.

46. Cuenda A, Rousseau S (2007) p38 MAP-kinas pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375. doi:10.1016/j.bbamcr.2007.03.010. PubMed: 17481747.

47. Lee CH, Moon CH, Moon HJ, Park HJ, Choi JH, Park do Y (2013) S100A8 and S100A9 promotes invasion and migration through p38 mitogen-activated protein kinase-dependent NF-kappaB activation in gastric cancer cells. Mol Cells 35: 226-234. doi:10.1007/s10059-013-2269-x. PubMed: 23060292.

48. Wang XF, Zhou QM, Du J, Zhang H, Lu YY et al. (2013) Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway. Anti Cancer Agents Med Chem 13: 923-931. doi:10.2174/1871126131309001143. PubMed: 23357075.

49. Nuriwida F, Takahashi F, Murakami A, Takahashi K (2012) Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44: 151-156. doi:10.4143/cirt.2012.44.3.151. PubMed: 23091440.

50. Palacios F, Tushir JS, Fujita Y, D'Souza-Schorey C (2005) Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol 25: 389-402. doi:10.1128/MCB.25.1.389-402.2005. PubMed: 15601859.